BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Health Booster

14 July 2006 | News





Health Booster

GE Healthcare's vision for the future is to enable a new 'early health' model of care focused on early diagnosis, pre-symptomatic disease detection and disease prevention.

GE is a diversified company with each of its businesses managing their own staffing needs, including foreign assignments. GE Healthcare provides transformational medical technologies and its expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. The company's vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the UK, GE Healthcare is a $15 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 43,000 people committed to serving healthcare professionals and their patients in more than 100 countries.

GE Healthcare is broadly divided into five areas of research, bioprocess, protein sciences, discovery sciences, genomic sciences and services. The company has equipment and reagents to target these four broad categories (plus services). Its India branch office is a direct marketing and sales office for the Global GEHC life sciences group. The products range from drug screening, cellular assays, cell processing, nucleotides, enzymes, biochemicals, radiochemicals, nucleic acid synthesis, amplification and purification, DNA sequencing, microarrays, proteomics, electrophoresis, spectrophotometry, blotting,

imaging and analysis and protein purification.

Recently GE announced a $250 million infrastructure investment in India, with projects targeted in infrastructure, healthcare and real estate. "Our target is to create sales and assets worth $8 billion by 2010. We will focus on infrastructure, while increasing our footprint in financial services, technology and developing business with our local partners," GE chairman and CEO, Jeff Immelt said. GE will be a partner in Dr Naresh Trehan's Medicity project, a world-class integrated healthcare facility in New Delhi. Beyond financial investment, GE will also provide end-to-end early disease prediction, diagnosis and monitoring tools like advanced medical diagnostics, Cathlabs and anesthesia systems, and partner in clinical research and education programs.

GE Healthcare is focusing on educating and implementing an early health model, while developing and introducing new products designed to meet specific Indian needs - delivering easier, earlier and more accurate care in locations with limited access to hospitals. It is setting up India's first radiopharmacy center in Delhi. The new radiopharmacy center will offer isotopes and radiopharmaceuticals in unit doses to various nuclear medicine hospitals and healthcare centers in and around Delhi. The company has planned additional radiopharmacy centers for Mumbai, Bangalore and Hyderabad. The center will be operational by the end of the year.

GE Healthcare is looking at entering the real-time label-free protein interaction analysis market by acquiring Biacore AB for SEK330 per share, an offer that values the company at SEK3.2 billion ($435.9m) or about SEK2.9 billion net of Biacore's cash reserves.